PRCT Earnings Date: Nov 4, 2026 (Estimated) — PROCEPT BioRobotics Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is PRCT's next earnings date?
PROCEPT BioRobotics Corporation (PRCT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.39 on revenue of $100.5M.
How did PRCT do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), PROCEPT BioRobotics Corporation posted EPS of -$0.47 versus the -$0.46 estimate, a miss of 2.2%. Revenue was $94.5M against a $92.8M estimate. The stock's 1-day post-earnings move was +5.8%.
How much does PRCT stock move after earnings?
PRCT beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.7% (up or down) in the day after earnings.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.46 | -0.47 | -2.17% | $94.5M | ❌ Miss | +5.80% | +25.22% | +20.19% |
| 2026-04-29 | Q1 2026 | -0.56 | -0.56 | +0.00% | $83.1M | ➖ Inline | +10.73% | +14.23% | +21.28% |
| 2026-02-25 | Q4 2025 | -0.32 | -0.53 | -65.62% | $76.4M | ❌ Miss | -15.12% | -4.60% | -9.95% |
| 2025-11-04 | Q3 2025 | -0.42 | -0.38 | +9.52% | $83.3M | ✅ Beat | -9.74% | -10.51% | +1.17% |
| 2025-08-06 | Q2 2025 | -0.41 | -0.35 | +14.63% | $79.2M | ✅ Beat | -13.35% | -11.62% | -10.97% |
| 2025-04-24 | Q1 2025 | -0.49 | -0.45 | +8.16% | $69.2M | ✅ Beat | -5.64% | -3.09% | +3.63% |
| 2025-02-25 | Q4 2024 | -0.35 | -0.35 | +0.00% | $68.2M | ➖ Inline | +8.61% | +3.62% | -0.61% |
| 2024-10-28 | Q3 2024 | -0.49 | -0.40 | +18.37% | $58.4M | ✅ Beat | +32.33% | +34.20% | +42.18% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $94.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 88.3% | $83.4M | +19.9% | $60.4M | $60.3M | $69.6M | $73.9M |
| Non-US | 11.7% | $11.1M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.